跳至主要内容
临床试验/KCT0000347
KCT0000347已完成未知

A Phase II Trial of RAD001 (Everolimus) for 2nd Line Treatment After Failure of Fluoropyrimidine Plus Platinum Chemotherapy in Patients With Metastatic or Recurrent Gastric Cancer With pS6 Ser 240/4 Expression

Asan Medical Center0 个研究点目标入组 45 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
45

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
20(Year) 至 75(Year)(—)
性别
All

入选标准

  • Pathologically proven non-resectable adenocarcinoma of stomach with measurable disease
  • -Prior failure (progression during or within 6 months after) of 1st line palliative chemotherapy including fluoropyrimidine (capecitabine, S-1, or 5-FU) and platinum (cisplatin or oxaliplatin) for metastatic or recurrent gastric cancer
  • -High expression of pS6 Ser 240/4 (proportion of pS6 Ser 240/4 positive cancer cells by immunohistochemistry > 10%)
  • -Age 20 to 75 years old
  • -Estimated life expectancy of more than 3 months
  • -ECOG performance status of 2 or lower
  • -Adequate bone marrow function
  • -Adequate kidney function
  • -Adequate liver function
  • -Written informed consent

排除标准

  • - Other tumor type than adenocarcinoma
  • - Presence or history of CNS metastasis
  • - Obvious bowel obstruction or active gastrointestinal bleeding
  • - Other serious illness or medical conditions

研究者

相似试验